Article

Intellectual Property Do's and Don'ts for Early-Stage Life Sciences Companies

Authors

Early-stage life sciences companies typically focus their time and resources on developing their core products, positioning them for commercial success, and, if applicable, obtaining Food and Drug Administration (FDA) approval. Intellectual property (IP) protection is often further down their list of priorities. This is a mistake. The strength of a company's IP assets is a critical factor in determining its value; failure to protect those assets can seriously diminish a company's prospects for long-term success. Savvy companies focus on IP early and integrate their IP strategies seamlessly into their overall business strategy.

Read the full article on Life Science Leader.

Read the full Life Sciences Entrepreneur Sourcebook.

The opinions expressed are those of the authors on the date noted above and do not necessarily reflect the views of Fish & Richardson P.C., any other of its lawyers, its clients, or any of its or their respective affiliates. This post is for general information purposes only and is not intended to be and should not be taken as legal advice. No attorney-client relationship is formed.